Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

When compared to the first quarter of fiscal 2008, license fees and royalties were higher by $67,000 or 51.1%. License fees and royalty revenues are comprised solely of royalties related to sales of Klean-Prep(TM) outside of Canada except in the first quarter of fiscal 2009 which includes a US$75,000 termination payment from Lumera Corporation.

Research and Development Contract Revenue

The Company had no research and development contract revenue in both the first quarters of fiscal 2009 and 2008.

Cost of sales and margins

Cost of sales totaled $447,000 in the first quarter of fiscal 2009 (2008 - $313,000). Margins, on a percentage basis, in the first quarter of fiscal 2009 were 51.5% (2008 - 58.5%). The decrease in margins reflects higher purchase costs resulting from a lower Canadian dollar versus both the U.S. dollar and the Euro. In addition, some competitive pricing in the current market has also resulted in lower pricing to customers.

Research & development

Research and development costs in the first quarter of fiscal 2009 totaled $1,641,000 (2008 - $782,000) for an increase of $859,000. Higher research and development costs in the first quarter of fiscal 2008 reflect increased costs for both L-DOS47 and Topical Interferon Alpha-2b programs with the latter representing the majority of the research and development expenditures in the quarter. Research and development expenditures were split relatively equally amongst the L-DOS47, LSIL and AGW initiatives, with slightly higher expenditures associated with AGW due to the activities to enhance patient enrollment including the expansion of the trial to open study centers in Germany.

Operating, general & administration

Operating, general and administration expenses in the first quarter of fiscal 2009 totaled $1,310,000 (2008 - $1,313,000), for a decrea
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, more ... In the military, burn injury is a ubiquitous ... care. More than 800 service members sustained burn ... slowly, remain inflamed and often become infected, producing ... functionally damaging. While developments in supportive care have ...
(Date:9/29/2014)... Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, Canadian ... three Promissory Note holders, two of whom are the ... July 2014 for a total of $ 300,000 opted ... 3,500,001 restricted common shares. Notes were repayable within one ... the coupon were convertible into common shares to be ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE ... precision balances as well as automated dosing ... can carry out their daily weighing tasks worry free, ... deliver consistently reliable and compliant results, thanks to new ... of the biggest challenges in analytical and micro-analytical weighing ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 2
... This release is available in German . ... in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together ... (TUM), have now presented a novel molecular switch in the ... the switch is the position of a single proton in ...
... COLUMBUS, Ohio, Dec. 12, 2011   Chemical Abstracts ... Chemical Society and the world,s authority for chemical ... InfoChem, GmbH (InfoChem), a  leader ... as datamining in chemical science documents, headquartered in ...
... Zyngenia , Inc ... antibody-based drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as ... our start in September 2009, Zyngenia has made tremendous progress in ...
Cached Biology Technology:The smallest conceivable switch 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 2CAS and InfoChem Enter Into Long Term Collaboration in ChemInformatics 3Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3
(Date:9/29/2014)... the age of dinosaurs, gigantic reptilesdistant relatives of modern ... in water and it was thought they didn,t much ... Tennessee, Knoxville, researcher in the thigh of one of ... Stephanie Drumheller, an earth and planetary sciences lecturer, and ... examined 220-million-year-old bite marks in the thigh bones of ...
(Date:9/29/2014)... considered capable of doing anything on their own. But ... water. In the future, such moving droplets may deliver ... to be self-moving is a feature normally ... be self-moving, report researchers from University of Southern Denmark ... , The researchers have made alcohol droplets move in ...
(Date:9/29/2014)... researchers at the University of Cambridge has shown that ... most of Greenland is more sensitive to climate change ... rising sea levels that threaten coastal communities worldwide. , ... levels of meltwater created and spilled into the ocean ... new model also takes into account the role that ...
Breaking Biology News(10 mins):Tooth serves as evidence of 220 million-year-old attack 2Scientists make droplets move on their own 2Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... a telescope promise to make it easier for people ... requiring sharper distance vision. Schepens Eye Research Institute scientists ... devices in an article published in the May/June issue ... in print form to subscribers this month. ...
... A new study by researchers from Columbia University,s ... most challenging issues in infant health and preventing mother-to-child ... HIV-infected mothers had been advised that for the best ... by a rapid weaning four to six months after ...
... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... immune response modifier with potent antiviral and antitumor activity, ... (OGFr) axis for its action. This discovery, reported ... and Medicine , provides new insights into a widely ...
Cached Biology News:Telescope embedded in glasses lens promises to make driving easier for visually impaired 2Telescope embedded in glasses lens promises to make driving easier for visually impaired 3Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
pH-insensitive fluorescence (pH 2-12)...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: